Abstract
Leptin has emerged as a major regulator of adiposity. Leptin is released into the blood from fatcells and circulates to the brain where it crosses the bloodbrain barrier (BBB) to act at receptors within the central nervous system to affect appetite, thermogenesis, and a number of other actions. In humansand in many rodent models, resistance to leptin appears to be a chief cause of obesity. Determining the cause of leptin resistance is fundamental to developing strategies for the use of leptin in obesity. Theliterature characterizing the transport of leptin across the BBB is reviewed. This literature stronglysuggests that the cause of leptin resistance is due a decreased transport of leptin across the BBB in obese humans and rodents. The main cause of this resistance appears to be an impairment in the activity of the transporter rather than just simply saturation at higher doses. Strategies to overcome impaired BBB transport are reviewed, including the use of allosteric regulators and the delivery of material by the intrathecal route.
Current Pharmaceutical Design
Title: Leptin Transport Across the Blood-Brain Barrier: Implications for the Cause and Treatment of Obesity
Volume: 7 Issue: 2
Author(s): William A. Banks
Affiliation:
Abstract: Leptin has emerged as a major regulator of adiposity. Leptin is released into the blood from fatcells and circulates to the brain where it crosses the bloodbrain barrier (BBB) to act at receptors within the central nervous system to affect appetite, thermogenesis, and a number of other actions. In humansand in many rodent models, resistance to leptin appears to be a chief cause of obesity. Determining the cause of leptin resistance is fundamental to developing strategies for the use of leptin in obesity. Theliterature characterizing the transport of leptin across the BBB is reviewed. This literature stronglysuggests that the cause of leptin resistance is due a decreased transport of leptin across the BBB in obese humans and rodents. The main cause of this resistance appears to be an impairment in the activity of the transporter rather than just simply saturation at higher doses. Strategies to overcome impaired BBB transport are reviewed, including the use of allosteric regulators and the delivery of material by the intrathecal route.
Export Options
About this article
Cite this article as:
William A. Banks , Leptin Transport Across the Blood-Brain Barrier: Implications for the Cause and Treatment of Obesity, Current Pharmaceutical Design 2001; 7 (2) . https://dx.doi.org/10.2174/1381612013398310
DOI https://dx.doi.org/10.2174/1381612013398310 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenetics and Statin Treatment: Reality or Theory?
Current Vascular Pharmacology Functional Genomics in Zebrafish as a Tool to Identify Novel Antiarrhythmic Targets
Current Medicinal Chemistry Immunoglobulin Therapy, Myocardial Diseases and Atherosclerosis:Recent Experimental and Clinical Studies
Current Cardiology Reviews A Comprehensive Review on <i>Onosma bracteata</i> Wall.: A Controversial Medicinal Herb in Ayurveda
Current Traditional Medicine Cardiovascular Risk Calculators and their Applicability to South Asians
Current Diabetes Reviews Patent Selections
Recent Patents on Cardiovascular Drug Discovery ISCHEMIRs: Finding a Way Through the Obstructed Cerebral Arteries
Current Drug Targets Pharmacological Targeting of Neuronal Kv7.2/3 Channels: A Focus on Chemotypes and Receptor Sites
Current Medicinal Chemistry Recent Progress in Pharmacological and Non-Pharmacological Treatment Options of Major Depression
Current Pharmaceutical Design Complementary Role of Herbal Medicine and Exercise in Cardiovascular Disease Prevention and Management: A Review of Evidence
Current Pharmaceutical Design Coronary Atherosclerotic Disease Burden: An Emerging Endpoint in Progression / Regression Studies Using Intravascular Ultrasound
Current Drug Targets - Cardiovascular & Hematological Disorders Molecular Link between Intravascular Hemolysis and Vascular Occlusion in Sickle Cell Disease
Current Vascular Pharmacology Thromboprophylaxis in Medical Patients: An Update
Vascular Disease Prevention (Discontinued) Nitric Oxide Therapies in Vascular Diseases
Current Pharmaceutical Design CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation Anthocyanins as a Potential Therapy for Diabetic Retinopathy
Current Medicinal Chemistry Galectin-3 in Blood Serum and Lymphocytes as a Marker of Myocardial Damage in Patients with Arterial Hypertension and COVID-19
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice
Current Pharmaceutical Design Cytokine Gene Polymorphism in Heart Transplantation: A Review
Current Genomics Contemporary Overview on Clinical Trials and Future Prospects of Hepato-protective Herbal Medicines
Reviews on Recent Clinical Trials